Dolutegravir based therapy showed CD4⁺ T cell count recovery and viral load suppression among ART naive people living with HIV AIDS: a pilot evaluation.

ABSTRACT: Recently, dolutegravir (DTG)-based combined therapy, a more effective and safer first-line antiretroviral therapy (ART), has been recommended by the World Health Organization for the treatment of Human Immunodeficiency Virus (HIV) since July 2018. However, its effectiveness in CD4⁺ T-cells count recovery and viral load suppression has not been studied yet in Ethiopia, where HIV is endemic. Therefore, we aimed to conduct a pilot assessment on the effect of DTG-based therapy on CD4⁺ T-cell count and viral load count among people living with HIV (PLWH) in Ethiopia. A longitudinal prospective cohort study was conducted from July 2020 to February 2021. 109 PLWH who are ART naive but plan to initiate DTG-based therapy were recruited. HIV viral ribonucleic acid (RNA) copies

SUBMITTER: Gebremedhin T 

PROVIDER: S-EPMC10853173 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature